

# **Adult Spectrum of HIV Disease (ASD)**

## **Semi-Annual Report**

### **New York City**

**New York City Department of Health and Mental Hygiene  
HIV Epidemiology Program (HEP)  
346 Broadway, Room 706  
January 2004**



## **Adult Spectrum of HIV Disease**

This report contains selected results on patients at three HIV/AIDS clinics in New York City who are being followed in the Adult Spectrum of HIV Disease Project (ASD). ASD is a longitudinal study of HIV-infected persons and is funded by the Centers for Disease Control and Prevention at 11 sites nationally. The project began in New York City in 1991.

Outpatient and inpatient medical records are reviewed at 6-month intervals for information on medical conditions, immunologic status, treatment and prophylaxis, and health care utilization. Patients are enrolled in ASD at their first clinic visit, and over time the enrollment ratio has ranged from 1:1 to 1:6 in order to maintain a steady sample size. The number of active ASD patients in New York City is currently 925.

Questions or comments about these results or requests for additional information can be addressed to Marie-Antoinette Bernard, MD, MPH, NYC Department of Health and Mental Hygiene, HIV Epidemiology Program (HEP), (212) 442-3491, DrMBernard@aol.com.

### **ASD Staff**

Judith Sackoff, PhD  
Marie Antoinette Bernard, MD, MPH

Melissa Riley Pfeiffer, MPH  
Eula Bryan

**Data Abstraction**  
Donna Thompson  
Ann-Marie Benjamin  
Colin Roach  
Athea Bullard

Principal Investigator  
Co-Principal Investigator,  
Medical Specialist  
Data Manager  
Field Supervisor

**Data Entry**  
Berthony Francois  
Fifi Laboissiere

**Research Assistant**  
Shavvy Raj-Singh, MPH

**Table 1. Demographic characteristics of active\* ASD patients. New York City ASD.**

	Male		Female		All	
	n	% <sup>†</sup>	n	% <sup>†</sup>	n	% <sup>†</sup>
<b>Age (current)</b>						
20-29	12	(2)	16	(4)	28	(3)
30-39	140	(24)	88	(25)	228	(25)
40-49	236	(41)	154	(44)	390	(42)
50-59	150	(26)	66	(19)	216	(23)
60+	38	(7)	24	(7)	62	(7)
<b>Race/ethnicity</b>						
White	42	(7)	14	(4)	56	(6)
Black	287	(48)	205	(59)	492	(53)
Hispanic	240	(42)	126	(36)	366	(40)
API/NA/Multi/UNK	8	(1)	3	(1)	11	(1)
<b>HIV risk category</b>						
MSM	149	(26)	0	(0)	149	(16)
IDU	202	(35)	94	(27)	296	(32)
Heterosexual	34	(6)	130	(37)	164	(18)
Other/Unknown	192	(33)	124	(36)	316	(34)
<b>Country of birth</b>						
US	263	(46)	201	(58)	464	(50)
US dependency (PR, VI)	84	(15)	32	(9)	116	(13)
Foreign	169	(29)	83	(24)	252	(27)
Unknown	61	(11)	32	(9)	93	(10)
<b>Total</b>	<b>577</b>	<b>(62)<sup>††</sup></b>	<b>348</b>	<b>(38)<sup>††</sup></b>	<b>925</b>	<b>(100)</b>


ABBREVIATIONS: API/NA/Multi/Unk, Asian/Pacific Islander/Native American/Alaskan/Multi-Racial/Unknown; MSM, men who have sex with men; IDU, injecting drug use; PR, Puerto Rico; VI, Virgin Islands

\* Active patients had at least one inpatient or outpatient visit in the second half of 2002 or in 2003.


<sup>†</sup> Column percents

<sup>††</sup> Row percents

**Figure 1. CD4+ at first visit among newly diagnosed HIV+ clinic patients, percent  $\geq 200$ , median and interquartile range. New York City ASD.**




**Figure 2. Percent of patients who stopped attending ASD site by length of time attending ASD site before stopping. New York City ASD.**



\*These patients did not seek care after their initial clinic visit.

**Figure 3. Antiretroviral regimens prescribed to ASD patients with CD4+ nadir <350 cells/ $\mu$ L, 1997-2003. New York City ASD.**




ABBREVIATIONS: NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. \*A PI regimen was defined as  $\geq 3$  drugs including  $\geq 1$  PI. An NNRTI regimen was defined as  $\geq 3$  drugs including  $\geq 1$  NNRTI. 2 NRTI regimen was defined as  $\geq 2$  NRTI without any PI or NNRTI. Other regimen was defined as any drug combination that did not fall in one of the prior categories.

Among patients with a CD4+ nadir <350, the percent not on any ART varied between 12% and 18% over time.

**Table 2. Antiretroviral resistance testing among active patients, by half year. New York City ASD.**

	99/2	00/1	00/2	01/1	01/2	02/1	02/2	03/1
Number of patients	828	936	874	781	743	872	815	625
Number of patients with resistance testing	8	33	82	71	60	98	98	42
Percent of patients with resistance testing	1.0	3.5	9.4	9.1	8.1	11.2	12.0	6.7

**Figure 4. Percent of active patients with a viral load test, 1998-2003. New York City ASD.**



**Figure 5. Distribution of most recent viral load of active patients, 1998-2003. New York City ASD.**

